dc.contributor.author | ALKAN, Sena | |
dc.contributor.author | KUTLUBAY, Zekayi | |
dc.contributor.author | ÇETİNKALE, Oğuz | |
dc.contributor.author | SALTOĞLU, Neşe | |
dc.contributor.author | TABAK, Ömer Fehmi | |
dc.contributor.author | METE, Bilgül | |
dc.contributor.author | MURT, Ahmet | |
dc.contributor.author | Ozdemir, Yusuf Emre | |
dc.contributor.author | BALKAN, İlker İnanç | |
dc.contributor.author | Bayramlar, Osman Faruk | |
dc.contributor.author | KARAALİ, Rıdvan | |
dc.contributor.author | KUŞKUCU, Mert Ahmet | |
dc.contributor.author | AYGÜN, Gökhan | |
dc.contributor.author | KESKİNDEMİRCİ, Yılmaz | |
dc.contributor.author | ÖNGÖREN, Şeniz | |
dc.date.accessioned | 2021-12-10T12:57:50Z | |
dc.date.available | 2021-12-10T12:57:50Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Ozdemir Y. E. , BALKAN İ. İ. , Bayramlar O. F. , ALKAN S., MURT A., KARAALİ R., METE B., KUŞKUCU M. A. , AYGÜN G., KESKİNDEMİRCİ Y., et al., "Clinical Characteristics of Mild-Moderate COVID-19 Patients and Risk Factors for the Development of Pneumonia", MIKROBIYOLOJI BULTENI, cilt.55, sa.3, ss.342-356, 2021 | |
dc.identifier.issn | 0374-9096 | |
dc.identifier.other | av_e4f5366e-04ac-4f98-a63d-bcb916676ee2 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/175098 | |
dc.identifier.uri | https://doi.org/10.5578/mb.20219805 | |
dc.description.abstract | Limited data exists to date on the predictors for the development of pneumonia in patients with mild and moderate coronavirus (COVID-19). In this study, it was aimed to evaluate the demographic characteristics and clinical findings of mild and moderate COVID-19 and to determine the risk factors for the development of COVID-19 pneumonia in patients admitted to the pandemic outpatient clinic of a university hospital. A total of 414 patients with laboratory confirmed COVID-19 were included. Of these, 220 (53.1%) were male, the mean age was 38.3 +/- 12.7. Median duration of hospital admission from the onset of symptoms was three days (0-11). Of the confirmed COVID-19 cases, 154 (37.2%) had a history of family contact and the most common symptoms were weakness (68.4%), myalgia (61.8%), headache (56.5%), loss of smell (45.2%), loss of taste (43.2%) and anorexia (42.8%). Among females, weakness (p= 0.016), headache (p= 0.008), sore throat (p= 0.032), nausea (p= 0.003), anorexia (p= 0.045), loss of taste (p= 0.005) and loss of smell (p30 were high, and 60.9% of the patients had pneumonia (p< 0.001). CRP (p< 0.001), D-dimer (p= 0.010) values were low, lymphocyte count (p= 0.001) was high among 106 (25.6%) active smokers, and 15.6% of the patients had pneumonia (p< 0.001). Of the patients reported with persistent symptoms, 25.9% had loss of smell, 25% had weakness, and 23.1% had loss of taste on the seventh day; 21.1% had loss of smell, 21.1% had myalgia, and 19.7% had loss of taste on the 14th day. During their follow-up, the COVID-19 polymerase chain reaction (PCR) test was studied in 286 patients for control purposes. The median time of being negative for COVID-19 PCR test was eight days (3-56). In conclusion, symptoms may last longer than 14 days in 20-30% of patients presenting with mild-moderate clinical findings. In addition, obesity should be considered as an important risk factor for COVID-19 pneumonia. | |
dc.language.iso | eng | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Mikrobiyoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Temel Bilimler | |
dc.title | Clinical Characteristics of Mild-Moderate COVID-19 Patients and Risk Factors for the Development of Pneumonia | |
dc.type | Makale | |
dc.relation.journal | MIKROBIYOLOJI BULTENI | |
dc.contributor.department | Bakirkoy Dr. Sadi Konuk Research & Training Hospital , , | |
dc.identifier.volume | 55 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 342 | |
dc.identifier.endpage | 356 | |
dc.contributor.firstauthorID | 2696007 | |